MONDAY, Aug. 19, 2019 -- Rozlytrek (entrectinib), a kinase inhibitor, has received approval to treat adults and adolescents with cancer that carries the genetic defect neurotrophic tyrosine receptor kinase (NTRK) gene fusion and has progressed...
Original Article: Rozlytrek Approved to Treat Tumors With NTRK Gene Fusion